Richetta A, Mattozzi C, Carlomagno V, Maiani E, Carboni V, Giancristoforo S, D'Epiro S, Bruni F, Calvieri S
Department of Cutaneous and Venereal Diseases and Plastic Surgery, Policlinico Umberto I, University of Rome La Sapienza, Rome, Italy.
Dermatol Online J. 2008 Nov 15;14(11):9.
Anti-tumor necrosis factor (anti-TNF-alpha) are a group of new drugs able to inhibit the action of this cytokine. Although systemic side effects have been well described, cutaneous adverse reactions have not yet been clearly elucidated. The authors report a case of a 29-year-old man affected by Crohn disease and ankylosing spondylitis who developed psoriatic lesions after IV infusion of infliximab 5 mg/Kg. The patient underwent cyclosporine treatment after interruption of biological therapy, and had complete resolution of cutaneous lesions. The reason for this phenomenon is not clear, Obviously more studies are necessary to define more clearly this paradoxical reaction. In addition, dermatologists must be informed about this potential cutaneous adverse event.
抗肿瘤坏死因子（抗TNF-α）是一类能够抑制这种细胞因子作用的新药。尽管全身性副作用已有详尽描述，但皮肤不良反应尚未得到明确阐释。作者报告了一例29岁患有克罗恩病和强直性脊柱炎的男性患者，其在静脉输注5毫克/千克英夫利昔单抗后出现了银屑病皮损。该患者在中断生物治疗后接受了环孢素治疗，皮肤损害完全消退。这种现象的原因尚不清楚，显然需要更多研究来更明确地界定这种矛盾反应。此外，必须让皮肤科医生了解这种潜在的皮肤不良事件。
